We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Veeva Systems' AI & Vault CRM Strength Signal More Upside Ahead
Read MoreHide Full Article
Key Takeaways
VEEV surpassed 125 live Vault CRM customers, including several top-20 biopharma companies.
Veeva gained Vault CRM commitments from Novo Nordisk, Roche and Merck & Co. recently.
VEEV's AI tools, recurring revenue base and healthy margins continue supporting growth.
Veeva Systems (VEEV - Free Report) continues to benefit from strong momentum across its Vault platform and growing adoption of Vault CRM, positioning the company well for sustained long-term growth. Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution for biopharma companies of all sizes in all regions. Vault CRM Suite also includes Events Management, Service Center, Campaign Manager and Patient CRM.
The company recently announced that more than 125 customers worldwide are now live on Vault CRM, including multiple top-20 biopharma companies across the United States, Europe and Japan. Management noted that growing adoption of Vault CRM alongside Veeva AI is accelerating the industry’s transition toward agentic CRM and AI-powered commercial engagement.
Veeva Systems’ momentum has also been supported by several large pharmaceutical companies committing to Vault CRM in recent months. In January 2026, Novo Nordisk announced that its International Operations business unit selected Vault CRM to strengthen commercial execution and support AI-driven customer engagement. Earlier, Roche expanded its partnership with Veeva Systems by adopting Vault CRM across its global pharma organization, while Merck & Co. committed to the platform to support one of its largest upcoming launch cycles.
These customer wins highlight increasing confidence in Veeva Systems’ cloud ecosystem, data integration capabilities and AI-enabled workflow tools. Apart from innovation-led growth, the company’s healthy margins, recurring revenue base and strong cash-generation capabilities remain additional positives for investors.
Peers Updates
Salesforce (CRM - Free Report) continues to strengthen its enterprise AI portfolio through expanding Agentforce capabilities and strategic partnerships. The company recently collaborated with HealthEx, Verily and Viz.ai to launch AI-powered healthcare agents aimed at improving clinical and administrative workflow efficiency.
Salesforce has also deepened partnerships with OpenAI and Anthropic to enhance Agentforce 360 with advanced generative AI functionality, while expanding tools for developers and partners. These initiatives are expected to strengthen Salesforce’s position in enterprise AI and support broader adoption across healthcare and other regulated industries.
IQVIA (IQV - Free Report) also continues to expand its AI and drug discovery capabilities through strategic initiatives. The company recently launched IQVIA.ai in collaboration with NVIDIA to enhance workflow automation and decision-making across clinical and commercial operations.
IQVIA also strengthened its early-stage research presence through the acquisition of select drug discovery assets from Charles River Laboratories. Additionally, the company partnered with Duke Clinical Research Institute to advance obesity and related disease research, further expanding its clinical development ecosystem.
VEEV’s Price Performance, Valuation and Estimates
Shares of VEEV have plunged 28.6% in the year-to-date period compared with the industry’s decline of 22.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, VEEV trades at a price-to-book ratio of 3.63, below the industry average. VEEV carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Veeva Systems' fiscal 2027 earnings implies a 9.4% improvement from the year-ago period.
View the Zacks #1 Rank List
Image: Bigstock
Veeva Systems' AI & Vault CRM Strength Signal More Upside Ahead
Key Takeaways
Veeva Systems (VEEV - Free Report) continues to benefit from strong momentum across its Vault platform and growing adoption of Vault CRM, positioning the company well for sustained long-term growth. Vault CRM is part of the Vault CRM Suite of applications that provide the technology foundation for commercial execution for biopharma companies of all sizes in all regions. Vault CRM Suite also includes Events Management, Service Center, Campaign Manager and Patient CRM.
The company recently announced that more than 125 customers worldwide are now live on Vault CRM, including multiple top-20 biopharma companies across the United States, Europe and Japan. Management noted that growing adoption of Vault CRM alongside Veeva AI is accelerating the industry’s transition toward agentic CRM and AI-powered commercial engagement.
Veeva Systems’ momentum has also been supported by several large pharmaceutical companies committing to Vault CRM in recent months. In January 2026, Novo Nordisk announced that its International Operations business unit selected Vault CRM to strengthen commercial execution and support AI-driven customer engagement. Earlier, Roche expanded its partnership with Veeva Systems by adopting Vault CRM across its global pharma organization, while Merck & Co. committed to the platform to support one of its largest upcoming launch cycles.
These customer wins highlight increasing confidence in Veeva Systems’ cloud ecosystem, data integration capabilities and AI-enabled workflow tools. Apart from innovation-led growth, the company’s healthy margins, recurring revenue base and strong cash-generation capabilities remain additional positives for investors.
Peers Updates
Salesforce (CRM - Free Report) continues to strengthen its enterprise AI portfolio through expanding Agentforce capabilities and strategic partnerships. The company recently collaborated with HealthEx, Verily and Viz.ai to launch AI-powered healthcare agents aimed at improving clinical and administrative workflow efficiency.
Salesforce has also deepened partnerships with OpenAI and Anthropic to enhance Agentforce 360 with advanced generative AI functionality, while expanding tools for developers and partners. These initiatives are expected to strengthen Salesforce’s position in enterprise AI and support broader adoption across healthcare and other regulated industries.
IQVIA (IQV - Free Report) also continues to expand its AI and drug discovery capabilities through strategic initiatives. The company recently launched IQVIA.ai in collaboration with NVIDIA to enhance workflow automation and decision-making across clinical and commercial operations.
IQVIA also strengthened its early-stage research presence through the acquisition of select drug discovery assets from Charles River Laboratories. Additionally, the company partnered with Duke Clinical Research Institute to advance obesity and related disease research, further expanding its clinical development ecosystem.
VEEV’s Price Performance, Valuation and Estimates
Shares of VEEV have plunged 28.6% in the year-to-date period compared with the industry’s decline of 22.1%.
Image Source: Zacks Investment Research
From a valuation standpoint, VEEV trades at a price-to-book ratio of 3.63, below the industry average. VEEV carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for Veeva Systems' fiscal 2027 earnings implies a 9.4% improvement from the year-ago period.
Image Source: Zacks Investment Research
The company currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.